CNS Pharmaceuticals (NASDAQ:CNSP) Raised to Buy at Maxim Group

CNS Pharmaceuticals (NASDAQ:CNSP) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a $0.50 price objective on the stock. Maxim Group’s target price suggests a potential upside of 252.11% from the company’s current price.

CNS Pharmaceuticals Price Performance

Shares of CNS Pharmaceuticals stock opened at $0.14 on Tuesday. CNS Pharmaceuticals has a one year low of $0.10 and a one year high of $137.50. The stock’s 50-day moving average is $0.57 and its 200 day moving average is $7.62. The firm has a market cap of $204,906.00, a price-to-earnings ratio of 0.00 and a beta of 2.58.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC grew its stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent reporting period. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.